Neurofibromatosis type 1 associated with papillary thyroid carcinoma incidentally detected by thyroid ultrasonography: a case report
© Kim et al.; licensee BioMed Central Ltd. 2012
Received: 20 January 2012
Accepted: 11 April 2012
Published: 2 July 2012
Neurofibromatosis type 1 is a common heritable neurocutaneous disorder. Neurofibromatosis type 1 may be associated with tumors of the central nervous system and pheochromocytoma. However, papillary thyroid carcinoma associated with neurofibromatosis type 1 is very rare. We present what is, to the best of our knowledge, the first case of papillary thyroid carcinoma to be detected incidentally by ultrasonography in a patient with neurofibromatosis type 1.
A 63-year-old South Korean man with neurofibromatosis type 1 presented to our study hospital because of thyroid nodules detected incidentally by ultrasonography. Papillary thyroid carcinoma was diagnosed by ultrasonography-guided fine-needle aspiration, and then a total thyroidectomy with central compartment neck dissection was performed. The B isoform of the RafV600E mutation was identified by multiplex real-time polymerase chain reaction assay.
Papillary thyroid carcinoma associated with neurofibromatosis type 1 is very rare. However, it is speculated that papillary thyroid carcinoma is more likely to be detected in patients with neurofibromatosis type 1 if screening by ultrasonography is performed for them.
Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder in which tumors involving the sheaths or peripheral nerves are associated with café-au-lait spots. NF1 is caused by mutation of the NF1 gene on chromosome 17q11.2 . The NF1 gene encodes for neurofibromin, which acts as a tumor-suppressor protein. NF1 may be associated with other tumors of the central nervous system, including optic glioma, glioblastoma, and meningioma, and rarely with pheochromocytoma. However, papillary thyroid carcinoma (PTC) associated with NF1 is very rare, and only three cases – all of which involved large tumors – have been reported in the literature [2–4]. Recently, the PTC of a patient with NF1 was diagnosed incidentally by thyroid ultrasonography (US). To the best of our knowledge, it is the first case of PTC to be detected incidentally by US in a patient with NF1.
A solid skin tumor was visible as a gray-white round mass. The outer surface was surrounded by a thin capsule, and the cut surface was homogenously gray-white. A microscopic examination showed that this tumor consisted of spindle-shaped cells with wavy and tapered nuclei. The cells showed positive staining for S-100, and a neurofibroma was diagnosed.
At present, our patient is following up as an out-patient. Radioactive iodine treatment is planned for adjuvant therapy of the papillary carcinoma.
NF1, also known as von Recklinghausen disease, is an autosomal dominant multisystem disorder that affects approximately 1 in 3500 people . In 1987, seven cardinal diagnostic criteria for NF1 were established . If any two of the following seven criteria are met, a diagnosis of NF1 is made: (a) two or more neurofibromas on or under the skin or one plexiform neurofibroma, (b) freckling of the groin or the axilla (arm pit), (c) six or more café-au-lait spots measuring 5mm in the greatest diameter in prepubescent individuals and over 15mm in the greatest diameter in post-pubescent individuals, (d) skeletal abnormalities such as sphenoid dysplasia or thinning of the cortex of the long bones of the body, (e) two or more Lisch nodules (hamartomas of the iris), (f) optic glioma, or (g) a first-degree relative with NF1. These diagnostic criteria are highly specific to adults with NF1. The patient in this study presented with neurofibromas all over the surface of his body, multiple café-au-lait spots, and axillary freckling. The NF1 gene was discovered in 1990. Mutational analysis is now available in a clinical setting and is useful for diagnostic confirmation of individuals who do not fulfill diagnostic criteria or when a prenatal diagnosis is desired .
Neurofibromatosis is an autosomal dominant disorder, meaning that only one copy of the affected gene is needed for the disorder to develop. Therefore, if only one parent has neurofibromatosis, his or her children have a 50% chance of developing the condition as well. The severity in affected individuals can vary and this variation may be due to variable expressivity. An individual with mild clinical symptoms can have a more severe phenotype and so genetic counseling is important . Approximately half of the known cases are due to de novo mutations and no other affected family members are seen. The patient in this case had no family history of NF1, suggesting that he has a de novo mutation.
PTC is one of the most common types of endocrine cancer. The prevalence of thyroid cancer is rapidly increasing in South Korea, and most cases are PTC. The high rates of incidence of RET/PTC rearrangements or point mutations in RAS and c-MET oncogenes are genetic hallmarks of PTC . The BRAF kinase is a serine-threonine kinase that mediates signal transduction through the MEK-ERK pathway. An activating mutation of the BRAF kinase gene, located on exon 15, was recently found to result in a valine-to-glutamic acid substitution at amino acid 600 (BRAF V600E mutation) that is an oncogene in human cancer and the most common mutation in PTC . In recent years, the BRAF V600E mutation has shown a high specificity for PTC, and its prevalence is highly variable, ranging from 30% to more than 80%, depending on the study. In the present study, the BRAF V600E mutation was identified by multiplex real-time PCR. This method is as sensitive as dual-priming oligonucleotide-based multiplex PCR (Seegene) for detecting BRAFV600E mutations.
The NF1 gene located on chromosome 17q11.2 encodes neurofibromin. The Ras-GAP is a potentially functional domain of neurofibromin . The Ras-GAP-related domain (Ras-GRD) accelerates the conversion of active Ras-GTP to inactive Ras-GDP in various cell types and acts as a negative regulator of the p21ras signaling pathway . Ras GTPases interact with multiple pathways, including the RAF-MEK-ERK mitogen-activated protein kinase pathway. Mutations in the NF1 gene result in abnormal cell growth and in the formation of benign and malignant tumors . Because BRAF V600E mutation and NF1 gene mutation are both involved in the MEK-ERK pathway, Koksal et al. suggested that the development of PTC in patients with NF1 may be associated with the ras gene but that further evidence is necessary to confirm this association.
PTCs are very rare in NF1. Only three cases have been reported. Nakamura et al. reported a case of NF1 associated with a pheochromocytoma and PTC in a 58-year-old woman. Hashiba et al. reported a case of skull metastasis from PTC in a 74-year-old woman with NF1. Koksal et al. reported neurofibroma adjacent to the thyroid gland and PTC in a patient with NF1. These cases all involved large tumors. The nodule in this study was small and was incidentally diagnosed by thyroid US. US features of malignant nodules include the presence of microcalcifications, hypoechogenicity, and irregular margins and the absence of a halo, predominantly solid composition, and intra-nodular vascularity . The nodule in this case had irregular margins, hypoechogenicity, microcalcifications, and extracapsular extension on US. This nodule was suspected to be associated with PTC, and a US-guided FNAB was performed at the thyroid nodule. The diagnosis based on FNA cytology indicated suspicious PTC. A total thyroidectomy with central compartment neck dissection of the thyroid tumor was performed. The tumor in the left thyroid lobe was diagnosed as PTC, and metastasis of seven central lymph nodes at left level VI was confirmed.
NF1 is a common heritable neurocutaneous disorder. However, PTC associated with NF1 is very rare and only three cases have been reported. To the best of our knowledge, this is the first case of PTC to be detected incidentally by US in a patient with NF1. It is speculated that PTC is more likely to be detected in patients with NF1 if screening by ultrasound is performed.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
B isoform of the Raf
fine-needle aspiration biopsy
neurofibromatosis type 1
polymerase chain reaction
papillary thyroid carcinoma
Yasuhiro Ito and Akira Miyauchi, who are surgeons from the Department of Surgery, Kuma Hospital, Kobe, Japan, read this paper and provided expert revision.
- Viskochil D, Buchberg AM, Xu G, Cawthon RM, Stevens J, Wolff RK, Culver M, Carey JC, Copeland NG, Jenkins NA: Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus. Cell. 1990, 62: 187-192. 10.1016/0092-8674(90)90252-A.View ArticlePubMedGoogle Scholar
- Hashiba T, Maruno M, Fujimoto Y, Suzuki T, Wada K, Isaka T, Izumoto S, Yoshimine T: Skull metastasis from papillary thyroid carcinoma accompanied by neurofibromatosis type 1 and pheochromocytoma: report of a case. Brain Tumor Pathol. 2006, 23: 97-100. 10.1007/s10014-006-0203-z.View ArticlePubMedGoogle Scholar
- Koksal Y, Sahin M, Koksal H, Esen H, Sen M: Neurofibroma adjacent to the thyroid gland and a thyroid papillary carcinoma in a patient with neurofibromatosis type 1: report of a case. Surg Today. 2009, 39: 884-887. 10.1007/s00595-008-3946-9.View ArticlePubMedGoogle Scholar
- Nakamura H, Koga M, Higa S, Sato B, Noma K, Morimoto Y, Kishimoto S, Nakano E, Sonoda T: A case of von Recklinghausen’s disease associated with pheochromocytoma and papillary carcinoma of the thyroid gland. Endocrinol Jpn. 1987, 34: 545-551. 10.1507/endocrj1954.34.545.View ArticlePubMedGoogle Scholar
- Huson S, Compston D, Clark P, Harper P: A genetic study of von Recklinghausen neurofibromatosis in south east Wales. I. Prevalence, fitness, mutation rate, and effect of parental transmission on severity. J Med Genet. 1989, 26: 704-711. 10.1136/jmg.26.11.704.View ArticlePubMedPubMed CentralGoogle Scholar
- National institutes of health consensus development conference: Neurofibromatosis conference statement. Arch Neurol. 1988, 45: 575-578.View ArticleGoogle Scholar
- Boyd KP, Korf BR, Theos A: Neurofibromatosis type 1. J Am Acad Dermatol. 2009, 61: 1-14. 10.1016/j.jaad.2008.12.051.View ArticlePubMedPubMed CentralGoogle Scholar
- Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005, 12: 245-262. 10.1677/erc.1.0978.View ArticlePubMedGoogle Scholar
- Jouhilahti EM, Peltonen S, Heape AM, Peltonen J: The Pathoetiology of Neurofibromatosis 1. Am J Pathol. 2011, 178: 1932-1939. 10.1016/j.ajpath.2010.12.056.View ArticlePubMedPubMed CentralGoogle Scholar
- Martin GA, Viskoohil D, Bollag G, McCabe PC, Crosier WJ, Haubruck H, Conroy L, Clark R, O’Connell P, Cawthon RM: The GAP-related domain of the neurofibromatosis type 1 gene product interacts with ras p21. Cell. 1990, 63: 843-849. 10.1016/0092-8674(90)90150-D.View ArticlePubMedGoogle Scholar
- Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM: Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metabol. 2002, 87: 1941-1946. 10.1210/jc.87.5.1941.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.